Expanded Access Policy

SCYNEXIS development resources are focused on conducting clinical studies required by regulatory authorities to fully answer important scientific questions about the potential risks and benefits of our investigational products, and to obtain regulatory approval.

SCYNEXIS is committed to positively impacting the lives of patients suffering from fungal infections, and when possible, making our investigational products available to seriously ill patients who have exhausted other treatment options. Currently, SCYNEXIS is not able to supply product for new expanded access patients.